Oramed Receives Additional $4 Million Milestone Payment From HTIT

Totaling $25.5 M in payments from HTIT received to date

JERUSALEM, August 2, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, today announced it has received a milestone payment of $4 million from Hefei Tianhui Incubator of Technologies Co. […]

Categories: Press Releases|Tags: |

Oramed Reports Additional Phase IIb Oral Insulin Study Data Demonstrating Significant Lowering of Glucose Levels vs Placebo

JERUSALEM, July 28, 2016 /PRNewswire/ —

Statistically Significant Results Across Key Glycemic Endpoints 

Conference Call Today at 11:00 AM ET 

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, today reported additional data from the recently concluded Phase IIb trial […]

Categories: Press Releases|Tags: |

Oramed Appoints Dr. Roy Eldor as Chief Medical Director

JERUSALEM, July 26, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Roy Eldor MD PhD to the newly created position of Chief Medical Director.

“We are very pleased to welcome Dr. Eldor on […]

Categories: Press Releases|Tags: |

Oramed Announces $6.5 Million Milestone Payment from HTIT

Payment comes in wake of positive topline phase IIB results

JERUSALEM, June 21, 2016 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, today announced that Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT) is transferring a $6.5 million milestone […]

Categories: Press Releases|Tags: |

Oramed to Present at the American Diabetes Association 76th Scientific Sessions

JERUSALEM, June 9, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing a study performed in animals with its orally ingestible insulin capsule, ORMD-0801, will be presented […]

Categories: Press Releases|Tags: |

Oramed Announces Positive Top-Line Results from Phase IIb Oral Insulin Study

All Primary Safety and Efficacy Endpoints Were Met; Conference Call Today at 11:00 am EDT

JERUSALEM, May 18, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), today announced positive top-line results from its Phase IIb study, designed to evaluate the safety and efficacy of its oral insulin […]

Categories: Press Releases|Tags: |

Oramed to Present at Oppenheimer Annual Israeli Conference

JERUSALEM, May 16, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Oppenheimer Annual Israeli Conference, taking place on May 22, 2016 in […]

Categories: Press Releases|Tags: |

Oramed Patent Being Granted in China for Oral Administration of Proteins

JERUSALEM, May 11, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that an official Notification of Granting Patent Right was issued for the Company’s patent for its invention titled “Methods and Compositions for Oral Administrations of […]

Categories: Press Releases|Tags: |

Oramed to Present at PIONEERS 2016, Presented by Joseph Gunnar

JERUSALEM, April 28, 2016
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar & Co. LLC, taking place on […]

Categories: Press Releases|Tags: |

Oramed Receives Patent Term Adjustment Extending the Term of Its U.S. Patent

Patent addresses platform technology for oral insulin capsule ORMD-0801

JERUSALEM, April 12, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the U.S. Patent and Trademark Office (PTO) has issued a […]

Categories: Press Releases|Tags: |